Methylprednisolone
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
Methylprednisolone: From Systemic Corticosteroid Therapy to Alopecia Areata
One-Sentence Summary
Methylprednisolone is a potent synthetic glucocorticoid, registered in South Africa as injectable products. The TxGNN model predicts it may be effective for alopecia areata. Support comes from 20 publications, all observational or review-level, and 1 directly relevant clinical trial (a completed Phase 4 study of oral pulse methylprednisolone). No randomised trial of methylprednisolone in this disease was identified.
Quick Overview
| Item | Content |
|---|---|
| Predicted New Indication | Alopecia areata |
| TxGNN Prediction Score | 99.99% (model rank 119) |
| Evidence Level | L3 (observational studies and reviews) |
| South Africa Market Status | Marketed |
| Number of SAHPRA Registrations | 3 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism of action data is not available in the Evidence Pack. Methylprednisolone is a glucocorticoid. Its immunosuppressive and anti-inflammatory effects are well established.
Alopecia areata is a T-cell-mediated autoimmune attack on hair follicles after they lose immune privilege. A glucocorticoid that suppresses T-cell activation and pro-inflammatory cytokines is therefore biologically plausible. Systemic pulse steroids are already used off-label for severe disease. Trials of JAK inhibitors and other immunomodulators in this disease support the immune-mediated model.
The clinical limits are relapse after tapering and cumulative steroid toxicity. Most of the methylprednisolone-specific support comes from retrospective and open-label studies.
Clinical Trial Evidence
Sixteen trials were retrieved. Most (about 12) are studies in systemic lupus erythematosus (SLE) of other agents, such as baricitinib and anifrolumab. Their auto-generated relevance notes refer to alopecia areata, which conflicts with the trial titles. I excluded them because they do not test methylprednisolone in alopecia. The trials that concern alopecia are:
| Trial Number | Phase | Status | Enrollment | Key Findings |
|---|---|---|---|---|
| NCT01167946 | Phase 4 | Completed | 42 | Oral mega-pulse methylprednisolone in severe, therapy-resistant alopecia areata, using higher doses and more frequent pulses. This is the only trial that directly tests the drug in the predicted indication. |
| NCT01017510 | N/A | Unknown | 20 | Compares a needle-free injector (Dermojet) with a standard syringe for intralesional steroid injection in alopecia areata. It tests a delivery technique, not methylprednisolone efficacy. |
| NCT07101471 | N/A | Completed | 296 | Observational safety and effectiveness study of tofacitinib in alopecia, with or without adjuvant prednisolone. It is not a methylprednisolone study. |
No SANCTR, PACTR or ICTRP trials were identified.
Literature Evidence
No RCTs were retrieved. The table lists the 10 most relevant of the 20 publications, with reviews first and then cohort studies.
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 32270396 | 2020 | Systematic Review | Dermatol Ther | Cyclosporine with and without systemic corticosteroids in alopecia areata; outcomes varied. |
| 37992355 | 2023 | Review | Dermatol Pract Concept | Reviews the efficacy, relapse rates, side effects and response predictors of pulse corticosteroid regimens. It notes that outcomes vary. |
| 36461625 | 2023 | Review | Pediatr Dermatol | Reviews pulse-dose corticosteroids in children with alopecia areata. It notes that dosing regimens are not well established. |
| 28378336 | 2017 | Review | Int J Dermatol | Reviews treatments for alopecia totalis and universalis. It states that no therapy was FDA-approved for these forms at the time. |
| 35986630 | 2022 | Cohort | Dermatol Ther | Retrospective study of 26 patients with extensive disease. It compared methylprednisolone alone (14) with methylprednisolone plus methotrexate (12). |
| 22426909 | 2012 | Cohort | Saudi Med J | Intensive oral mega-pulse methylprednisolone in severe, therapy-resistant alopecia areata. |
| 25566921 | 2015 | Cohort | Indian J Dermatol Venereol Leprol | IV methylprednisolone pulse therapy in severe, extensive, therapy-resistant alopecia areata. |
| 9777767 | 1998 | Cohort | J Am Acad Dermatol | Open prospective study of 45 patients. It tested a single IV pulse in patients with ongoing hair loss of under 12 months. |
| 25872976 | 2015 | Cohort | Pediatr Dermatol | Reports high relapse rates in severe childhood alopecia areata despite early IV methylprednisolone pulse therapy. |
| 30745958 | 2019 | Cohort | Open Access Maced J Med Sci | Methotrexate combined with mini-pulse methylprednisolone in severe alopecia areata (Vietnamese experience). |
South Africa Market Information
| Registration Number | Product Name | Dosage Form |
|---|---|---|
| Reg. No. 42/21.5.1/0309 | Mylan methylprednisolone powder for solu… | Injection |
| Reg. No. F/21.5.4/228 | Depo-Medrol With Lidocaine | Injection |
| Reg. No. 42/21.5.1/0311 | Mylan methylprednisolone powder for solu… | Injection |
All 3 registrations are injectable products. The registration records do not include approved indication text. Product names are truncated in the source data.
Safety Considerations
Please refer to the SAHPRA-approved Professional Information (PI) for safety information. Report adverse drug reactions to SAHPRA.
No drug interaction records were found in the Evidence Pack. Relapse after tapering and cumulative steroid toxicity are recognised limits of systemic pulse therapy in alopecia areata.
Conclusion and Next Steps
Decision: Hold
Rationale: The mechanism is plausible, and pulse methylprednisolone is already used off-label in severe alopecia areata. However, the evidence is limited to retrospective cohorts, open-label studies and reviews, with one Phase 4 trial and no randomised controlled comparison. The safety data gap for the SAHPRA package inserts is classed as blocking.
Other predictions for this drug are weaker:
- Idiopathic steroid-sensitive nephrotic syndrome is supported only by class-level glucocorticoid evidence (L4).
- Most other hair-loss entities are supported by model prediction alone (L5) and should stay on hold.
To proceed, the following is needed:
- The SAHPRA package insert warnings and contraindications, to clear the safety screen
- Mechanism of action data from DrugBank
- Published results and a critical appraisal of NCT01167946
- A controlled study, or a systematic comparison of methylprednisolone with other pulse regimens or JAK inhibitors
- A plan to monitor relapse and cumulative steroid toxicity
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.